Compare Pfizer Inc (PFE) vs iShares Silver Trust (SLV) Price & Performance

Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.

PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.

SLV, the iShares Silver Trust ETF, trades at $53.08, up 4.53% on the day, amid a broader precious metals rebound. Technical indicators are predominantly bearish, with moving averages signaling sell pressure, though short-term RSI suggests potential oversold conditions. Recent news highlights silver's sensitivity to interest rate expectations and geopolitical tensions, with supply deficits and industrial demand providing fundamental support. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver.

The outlook for SLV hinges on macroeconomic factors, including Fed policy and silver's dual role as a monetary and industrial metal. Risks include persistent rate hikes and dollar strength, but long-term demand drivers offer appreciation potential. Investors should weigh silver's volatility against its hedge attributes.